Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyMetyrosine
Identification
- Name
- Metyrosine
- Accession Number
- DB00765 (APRD01112)
- Type
- Small Molecule
- Groups
- Approved
- Description
An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma. (Martindale, The Extra Pharmacopoeia, 30th ed)
- Structure
Structure for DB00765 (Metyrosine)
- Synonyms
- (-)-alpha-Methyl-L-tyrosine
- (–)-α-methyl-L-tyrosine
- (S)-alpha-Methyltyrosine
- Methyltyrosine
- Metirosin
- Metirosina
- Métirosine
- Metirosine
- Metirosinum
- α-methyl-L-p-tyrosine
- α-methyl-p-tyrosine
- α-methyl-para-tyrosine
- α-MPT
- External IDs
- 357 O / L 588 / L 588357-0 / L-588357-0 / MK 781 / MK-781
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Demser Capsule 250 mg/1 Oral Aton Pharma, Inc. 1979-10-03 Not applicable US 
- Categories
- UNII
- DOQ0J0TPF7
- CAS number
- 672-87-7
- Weight
- Average: 195.2151
Monoisotopic: 195.089543287 - Chemical Formula
- C10H13NO3
- InChI Key
- NHTGHBARYWONDQ-JTQLQIEISA-N
- InChI
- InChI=1S/C10H13NO3/c1-10(11,9(13)14)6-7-2-4-8(12)5-3-7/h2-5,12H,6,11H2,1H3,(H,13,14)/t10-/m0/s1
- IUPAC Name
- (2S)-2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid
- SMILES
- C[[email protected]](N)(CC1=CC=C(O)C=C1)C(O)=O
Pharmacology
- Indication
For use in the treatment of patients with pheochromocytoma, for preoperative preparation of patients for surgery, management of patients when surgery is contraindicated, and chronic treatment of patients with malignant pheochromocytoma.
- Structured Indications
- Pharmacodynamics
In patients with pheochromocytoma, who produce excessive amounts of norepinephrine and epinephrine, administration of one to four grams of metyrosine per day has reduced catecholamine biosynthesis from about 35 to 80 percent as measured by the total excretion of catecholamines and their metabolites (metanephrine and vanillylmandelic acid). The maximum biochemical effect usually occurs within two to three days, and the urinary concentration of catecholamines and their metabolites usually returns to pretreatment levels within three to four days after metyrosine is discontinued. Most patients with pheochromocytoma treated with metyrosine experience decreased frequency and severity of hypertensive attacks with their associated headache, nausea, sweating, and tachycardia. In patients who respond, blood pressure decreases progressively during the first two days of therapy with metyrosine; after withdrawal, blood pressure usually increases gradually to pretreatment values within two to three days.
- Mechanism of action
Metyrosine inhibits tyrosine hydroxylase, which catalyzes the first transformation in catecholamine biosynthesis, i.e., the conversion of tyrosine to dihydroxyphenylalanine (DOPA). Because the first step is also the rate-limiting step, blockade of tyrosine hydroxylase activity results in decreased endogenous levels of catecholamines and their synthesis. This consequently, depletes the levels of the catecholamines dopamine, adrenaline and noradrenaline in the body,usually measured as decreased urinary excretion of catecholamines and their metabolites. One main end result of the catecholamine depletion is a decrease in blood presure.
Target Actions Organism ATyrosine 3-monooxygenase binderHuman - Absorption
Well absorbed from the gastrointestinal tract.
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
Little biotransformation, with catechol metabolites accounting for less than 1% of the administered dose.
- Route of elimination
Because the first step is also the rate-limiting step, blockade of tyrosine hydroxylase activity results in decreased endogenous levels of catecholamines, usually measured as decreased urinary excretion of catecholamines and their metabolites.
- Half life
3.4 to 3.7 hours
- Clearance
- Not Available
- Toxicity
Signs of metyrosine overdosage include those central nervous system effects observed in some patients even at low dosages. At doses exceeding 2000 mg/day, some degree of sedation or feeling of fatigue may persist. Doses of 2000-4000 mg/day can result in anxiety or agitated depression, neuromuscular effects (including fine tremor of the hands, gross tremor of the trunk, tightening of the jaw with trismus), diarrhea, and decreased salivation with dry mouth. The acute toxicity of metyrosine was 442 mg/kg and 752 mg/kg in the female mouse and rat respectively.
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 7-Nitroindazole 7-Nitroindazole may increase the sedative activities of Metyrosine. Experimental 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Metyrosine. Experimental Acebutolol Acebutolol may increase the hypotensive activities of Metyrosine. Approved, Investigational Acemetacin The therapeutic efficacy of Metyrosine can be decreased when used in combination with Acemetacin. Approved, Experimental, Investigational Acepromazine Acepromazine may increase the sedative activities of Metyrosine. Approved, Vet Approved Aceprometazine Aceprometazine may increase the sedative activities of Metyrosine. Approved Acetophenazine The risk or severity of adverse effects can be increased when Metyrosine is combined with Acetophenazine. Approved Adipiplon Adipiplon may increase the sedative activities of Metyrosine. Investigational Agomelatine Agomelatine may increase the sedative activities of Metyrosine. Approved, Investigational Alaproclate The risk or severity of adverse effects can be increased when Metyrosine is combined with Alaproclate. Experimental Alfaxalone Alfaxalone may increase the sedative activities of Metyrosine. Vet Approved Alfentanil Alfentanil may increase the sedative activities of Metyrosine. Approved, Illicit Alfuzosin Alfuzosin may increase the hypotensive activities of Metyrosine. Approved, Investigational Aliskiren Aliskiren may increase the hypotensive activities of Metyrosine. Approved, Investigational Allopregnanolone Allopregnanolone may increase the sedative activities of Metyrosine. Investigational Alphacetylmethadol Alphacetylmethadol may increase the sedative activities of Metyrosine. Experimental, Illicit Alphaprodine Alphaprodine may increase the sedative activities of Metyrosine. Illicit Alprazolam Alprazolam may increase the sedative activities of Metyrosine. Approved, Illicit, Investigational Alprenolol Alprenolol may increase the hypotensive activities of Metyrosine. Approved, Withdrawn Ambrisentan Metyrosine may increase the hypotensive activities of Ambrisentan. Approved, Investigational Amifostine Metyrosine may increase the hypotensive activities of Amifostine. Approved, Investigational Amineptine The risk or severity of adverse effects can be increased when Metyrosine is combined with Amineptine. Illicit, Withdrawn Amisulpride Amisulpride may increase the sedative activities of Metyrosine. Approved, Investigational Amitriptyline The risk or severity of adverse effects can be increased when Metyrosine is combined with Amitriptyline. Approved Amlodipine Amlodipine may increase the hypotensive activities of Metyrosine. Approved Amobarbital Amobarbital may increase the sedative activities of Metyrosine. Approved, Illicit Amoxapine The risk or severity of adverse effects can be increased when Metyrosine is combined with Amoxapine. Approved Amperozide Amperozide may increase the sedative activities of Metyrosine. Experimental Amphetamine Amphetamine may increase the hypotensive activities of Metyrosine. Approved, Illicit, Investigational Aripiprazole Aripiprazole may increase the sedative activities of Metyrosine. Approved, Investigational Articaine Articaine may increase the sedative activities of Metyrosine. Approved Asenapine Asenapine may increase the sedative activities of Metyrosine. Approved Atenolol Atenolol may increase the hypotensive activities of Metyrosine. Approved Avanafil Avanafil may increase the antihypertensive activities of Metyrosine. Approved Azaperone Azaperone may increase the sedative activities of Metyrosine. Investigational, Vet Approved Azelastine Azelastine may increase the sedative activities of Metyrosine. Approved Baclofen Baclofen may increase the sedative activities of Metyrosine. Approved Barbital Barbital may increase the sedative activities of Metyrosine. Illicit Barnidipine Metyrosine may increase the antihypertensive activities of Barnidipine. Approved Benazepril Benazepril may increase the hypotensive activities of Metyrosine. Approved, Investigational Bendroflumethiazide Bendroflumethiazide may increase the hypotensive activities of Metyrosine. Approved Benmoxin Benmoxin may increase the hypotensive activities of Metyrosine. Withdrawn Benperidol Benperidol may increase the sedative activities of Metyrosine. Approved, Investigational Benzocaine Benzocaine may increase the sedative activities of Metyrosine. Approved, Investigational Benzyl alcohol Benzyl alcohol may increase the sedative activities of Metyrosine. Approved Bepridil Bepridil may increase the hypotensive activities of Metyrosine. Approved, Withdrawn Betaxolol Betaxolol may increase the hypotensive activities of Metyrosine. Approved, Investigational Bethanidine Bethanidine may increase the hypotensive activities of Metyrosine. Approved Bietaserpine Bietaserpine may increase the hypotensive activities of Metyrosine. Experimental Bifeprunox The risk or severity of adverse effects can be increased when Metyrosine is combined with Bifeprunox. Investigational Bimatoprost Bimatoprost may increase the hypotensive activities of Metyrosine. Approved, Investigational Bisoprolol Bisoprolol may increase the hypotensive activities of Metyrosine. Approved Bosentan Bosentan may increase the hypotensive activities of Metyrosine. Approved, Investigational BQ-123 BQ-123 may increase the hypotensive activities of Metyrosine. Investigational Bretylium Bretylium may increase the hypotensive activities of Metyrosine. Approved Brexpiprazole The risk or severity of adverse effects can be increased when Metyrosine is combined with Brexpiprazole. Approved, Investigational Brimonidine Brimonidine may increase the antihypertensive activities of Metyrosine. Approved Brofaromine Brofaromine may increase the hypotensive activities of Metyrosine. Experimental Bromazepam Bromazepam may increase the sedative activities of Metyrosine. Approved, Illicit, Investigational Bromisoval Bromisoval may increase the sedative activities of Metyrosine. Experimental Bromperidol The risk or severity of adverse effects can be increased when Metyrosine is combined with Bromperidol. Approved, Investigational Brompheniramine Brompheniramine may increase the sedative activities of Metyrosine. Approved Brotizolam Brotizolam may increase the sedative activities of Metyrosine. Approved, Investigational, Withdrawn Bupivacaine Bupivacaine may increase the sedative activities of Metyrosine. Approved, Investigational Bupranolol Bupranolol may increase the hypotensive activities of Metyrosine. Approved Buprenorphine Buprenorphine may increase the sedative activities of Metyrosine. Approved, Illicit, Investigational, Vet Approved Buspirone Buspirone may increase the sedative activities of Metyrosine. Approved, Investigational Butabarbital Butabarbital may increase the sedative activities of Metyrosine. Approved, Illicit Butacaine Butacaine may increase the sedative activities of Metyrosine. Vet Approved Butalbital Butalbital may increase the sedative activities of Metyrosine. Approved, Illicit Butamben Butamben may increase the sedative activities of Metyrosine. Approved, Withdrawn Butaperazine The risk or severity of adverse effects can be increased when Metyrosine is combined with Butaperazine. Experimental Butethal Butethal may increase the sedative activities of Metyrosine. Approved, Illicit Butorphanol Butorphanol may increase the sedative activities of Metyrosine. Approved, Illicit, Vet Approved Cadralazine Cadralazine may increase the hypotensive activities of Metyrosine. Experimental Cafedrine Cafedrine may increase the hypotensive activities of Metyrosine. Investigational Candesartan Candesartan may increase the hypotensive activities of Metyrosine. Experimental Candesartan cilexetil Candesartan cilexetil may increase the hypotensive activities of Metyrosine. Approved Candoxatril Candoxatril may increase the hypotensive activities of Metyrosine. Experimental Canertinib Canertinib may increase the sedative activities of Metyrosine. Investigational Captopril Captopril may increase the hypotensive activities of Metyrosine. Approved Carbamazepine Carbamazepine may increase the sedative activities of Metyrosine. Approved, Investigational Carbinoxamine Carbinoxamine may increase the sedative activities of Metyrosine. Approved Carfentanil Carfentanil may increase the sedative activities of Metyrosine. Illicit, Investigational, Vet Approved Cariprazine The risk or severity of adverse effects can be increased when Metyrosine is combined with Cariprazine. Approved, Investigational Carisoprodol Carisoprodol may increase the sedative activities of Metyrosine. Approved Caroxazone Caroxazone may increase the hypotensive activities of Metyrosine. Withdrawn Carteolol Carteolol may increase the hypotensive activities of Metyrosine. Approved Carvedilol Carvedilol may increase the hypotensive activities of Metyrosine. Approved, Investigational Celiprolol Celiprolol may increase the hypotensive activities of Metyrosine. Approved, Investigational Cetirizine Cetirizine may increase the sedative activities of Metyrosine. Approved Chloral hydrate Chloral hydrate may increase the sedative activities of Metyrosine. Approved, Illicit, Investigational, Vet Approved Chlordiazepoxide Chlordiazepoxide may increase the sedative activities of Metyrosine. Approved, Illicit, Investigational Chlormezanone Chlormezanone may increase the sedative activities of Metyrosine. Approved, Investigational, Withdrawn Chloroprocaine Chloroprocaine may increase the sedative activities of Metyrosine. Approved Chlorothiazide Chlorothiazide may increase the hypotensive activities of Metyrosine. Approved, Vet Approved Chlorphenamine Chlorphenamine may increase the sedative activities of Metyrosine. Approved Chlorproethazine The risk or severity of adverse effects can be increased when Metyrosine is combined with Chlorproethazine. Experimental Chlorpromazine Chlorpromazine may increase the sedative activities of Metyrosine. Approved, Investigational, Vet Approved Chlorprothixene Chlorprothixene may increase the sedative activities of Metyrosine. Approved, Investigational, Withdrawn Chlorthalidone Chlorthalidone may increase the hypotensive activities of Metyrosine. Approved Chlorzoxazone Chlorzoxazone may increase the sedative activities of Metyrosine. Approved Cicletanine Cicletanine may increase the hypotensive activities of Metyrosine. Investigational Cilazapril Cilazapril may increase the hypotensive activities of Metyrosine. Approved Cinchocaine Cinchocaine may increase the sedative activities of Metyrosine. Approved, Vet Approved Citalopram The risk or severity of adverse effects can be increased when Metyrosine is combined with Citalopram. Approved Clemastine Clemastine may increase the sedative activities of Metyrosine. Approved, Investigational Clidinium Clidinium may increase the sedative activities of Metyrosine. Approved Clobazam Clobazam may increase the sedative activities of Metyrosine. Approved, Illicit clomethiazole clomethiazole may increase the sedative activities of Metyrosine. Investigational Clomipramine The risk or severity of adverse effects can be increased when Metyrosine is combined with Clomipramine. Approved, Investigational, Vet Approved Clonazepam Clonazepam may increase the sedative activities of Metyrosine. Approved, Illicit Clonidine Clonidine may increase the sedative activities of Metyrosine. Approved Clopenthixol Clopenthixol may increase the sedative activities of Metyrosine. Experimental Cloranolol Cloranolol may increase the hypotensive activities of Metyrosine. Experimental Clorazepate Clorazepate may increase the sedative activities of Metyrosine. Approved, Illicit Clothiapine Clothiapine may increase the sedative activities of Metyrosine. Experimental Clozapine Clozapine may increase the sedative activities of Metyrosine. Approved Cocaine Cocaine may increase the sedative activities of Metyrosine. Approved, Illicit Codeine Codeine may increase the sedative activities of Metyrosine. Approved, Illicit Cryptenamine Cryptenamine may increase the hypotensive activities of Metyrosine. Approved Cyamemazine The risk or severity of adverse effects can be increased when Metyrosine is combined with Cyamemazine. Approved Cyclizine Cyclizine may increase the sedative activities of Metyrosine. Approved Cyclobenzaprine Cyclobenzaprine may increase the sedative activities of Metyrosine. Approved Cyclopenthiazide Cyclopenthiazide may increase the hypotensive activities of Metyrosine. Experimental Cyclopropane Cyclopropane may increase the sedative activities of Metyrosine. Experimental Cyclothiazide Cyclothiazide may increase the hypotensive activities of Metyrosine. Approved Cyproheptadine Cyproheptadine may increase the sedative activities of Metyrosine. Approved Dantrolene Dantrolene may increase the sedative activities of Metyrosine. Approved, Investigational Dapiprazole Dapiprazole may increase the sedative activities of Metyrosine. Approved Dapoxetine The risk or severity of adverse effects can be increased when Metyrosine is combined with Dapoxetine. Investigational Debrisoquin Debrisoquin may increase the hypotensive activities of Metyrosine. Approved, Investigational Delapril Delapril may increase the hypotensive activities of Metyrosine. Experimental Deramciclane Deramciclane may increase the sedative activities of Metyrosine. Investigational Deserpidine Metyrosine may increase the hypotensive activities of Deserpidine. Approved Desflurane Desflurane may increase the sedative activities of Metyrosine. Approved Desipramine The risk or severity of adverse effects can be increased when Metyrosine is combined with Desipramine. Approved, Investigational Desloratadine Desloratadine may increase the sedative activities of Metyrosine. Approved, Investigational Desvenlafaxine The risk or severity of adverse effects can be increased when Metyrosine is combined with Desvenlafaxine. Approved, Investigational Detomidine Detomidine may increase the sedative activities of Metyrosine. Vet Approved Dexbrompheniramine Dexbrompheniramine may increase the sedative activities of Metyrosine. Approved Dexmedetomidine Dexmedetomidine may increase the sedative activities of Metyrosine. Approved, Vet Approved Dextromoramide Dextromoramide may increase the sedative activities of Metyrosine. Experimental, Illicit Dextropropoxyphene Dextropropoxyphene may increase the sedative activities of Metyrosine. Approved, Illicit, Investigational, Withdrawn Dezocine Dezocine may increase the sedative activities of Metyrosine. Approved, Investigational Diazepam Diazepam may increase the sedative activities of Metyrosine. Approved, Illicit, Investigational, Vet Approved Diazoxide Diazoxide may increase the hypotensive activities of Metyrosine. Approved Dibenzepin The risk or severity of adverse effects can be increased when Metyrosine is combined with Dibenzepin. Experimental Diethyl ether Diethyl ether may increase the sedative activities of Metyrosine. Experimental Diethylnorspermine Diethylnorspermine may increase the hypotensive activities of Metyrosine. Investigational Difenoxin Difenoxin may increase the sedative activities of Metyrosine. Approved, Illicit Dihydralazine Dihydralazine may increase the hypotensive activities of Metyrosine. Approved, Investigational Dihydrocodeine Dihydrocodeine may increase the sedative activities of Metyrosine. Approved, Illicit Dihydroetorphine Dihydroetorphine may increase the sedative activities of Metyrosine. Experimental, Illicit Dihydromorphine Dihydromorphine may increase the sedative activities of Metyrosine. Experimental, Illicit Diltiazem Diltiazem may increase the hypotensive activities of Metyrosine. Approved, Investigational Dimenhydrinate Dimenhydrinate may increase the sedative activities of Metyrosine. Approved Diphenhydramine Diphenhydramine may increase the sedative activities of Metyrosine. Approved, Investigational Diphenoxylate Diphenoxylate may increase the sedative activities of Metyrosine. Approved, Illicit Dixyrazine Dixyrazine may increase the sedative activities of Metyrosine. Experimental Doramectin Doramectin may increase the sedative activities of Metyrosine. Vet Approved Dorzolamide Dorzolamide may increase the hypotensive activities of Metyrosine. Approved Dosulepin The risk or severity of adverse effects can be increased when Metyrosine is combined with Dosulepin. Approved Doxazosin Doxazosin may increase the hypotensive activities of Metyrosine. Approved Doxepin The risk or severity of adverse effects can be increased when Metyrosine is combined with Doxepin. Approved, Investigational Doxylamine Doxylamine may increase the sedative activities of Metyrosine. Approved, Vet Approved DPDPE DPDPE may increase the sedative activities of Metyrosine. Experimental Droperidol The risk or severity of adverse effects can be increased when Metyrosine is combined with Droperidol. Approved, Vet Approved Drotebanol Drotebanol may increase the sedative activities of Metyrosine. Experimental, Illicit Duloxetine The risk or severity of adverse effects can be increased when Metyrosine is combined with Duloxetine. Approved Dyclonine Dyclonine may increase the sedative activities of Metyrosine. Approved Ecgonine Ecgonine may increase the sedative activities of Metyrosine. Experimental, Illicit Ecopipam Ecopipam may increase the sedative activities of Metyrosine. Investigational Efavirenz Efavirenz may increase the sedative activities of Metyrosine. Approved, Investigational Efonidipine Efonidipine may increase the hypotensive activities of Metyrosine. Approved, Investigational Eltanolone Eltanolone may increase the sedative activities of Metyrosine. Investigational Enalapril Enalapril may increase the hypotensive activities of Metyrosine. Approved, Vet Approved Enalaprilat Enalaprilat may increase the hypotensive activities of Metyrosine. Approved Endralazine Endralazine may increase the hypotensive activities of Metyrosine. Experimental Enflurane Enflurane may increase the sedative activities of Metyrosine. Approved, Investigational, Vet Approved Entacapone Entacapone may increase the sedative activities of Metyrosine. Approved, Investigational Epanolol Epanolol may increase the hypotensive activities of Metyrosine. Experimental Epoprostenol Epoprostenol may increase the hypotensive activities of Metyrosine. Approved Eprosartan Eprosartan may increase the hypotensive activities of Metyrosine. Approved Escitalopram The risk or severity of adverse effects can be increased when Metyrosine is combined with Escitalopram. Approved, Investigational Esmirtazapine The risk or severity of adverse effects can be increased when Metyrosine is combined with Esmirtazapine. Investigational Estazolam Estazolam may increase the sedative activities of Metyrosine. Approved, Illicit Eszopiclone Eszopiclone may increase the sedative activities of Metyrosine. Approved, Investigational Ethanol Ethanol may increase the sedative activities of Metyrosine. Approved Ethchlorvynol Ethchlorvynol may increase the sedative activities of Metyrosine. Approved, Illicit, Withdrawn Ethosuximide Ethosuximide may increase the sedative activities of Metyrosine. Approved Ethotoin Ethotoin may increase the sedative activities of Metyrosine. Approved Ethyl carbamate Ethyl carbamate may increase the sedative activities of Metyrosine. Withdrawn Ethyl chloride Ethyl chloride may increase the sedative activities of Metyrosine. Approved, Experimental, Investigational Ethyl loflazepate Ethyl loflazepate may increase the sedative activities of Metyrosine. Approved, Illicit Ethylmorphine Ethylmorphine may increase the sedative activities of Metyrosine. Approved, Illicit Etidocaine Etidocaine may increase the sedative activities of Metyrosine. Approved Etifoxine Etifoxine may increase the sedative activities of Metyrosine. Investigational, Withdrawn Etizolam Etizolam may increase the sedative activities of Metyrosine. Approved Etomidate Etomidate may increase the sedative activities of Metyrosine. Approved Etoperidone The risk or severity of adverse effects can be increased when Metyrosine is combined with Etoperidone. Withdrawn Etorphine Etorphine may increase the sedative activities of Metyrosine. Illicit, Vet Approved Ezogabine Ezogabine may increase the sedative activities of Metyrosine. Approved, Investigational Felbamate Felbamate may increase the sedative activities of Metyrosine. Approved Felodipine Felodipine may increase the hypotensive activities of Metyrosine. Approved, Investigational Fencamfamine Fencamfamine may increase the sedative activities of Metyrosine. Approved, Illicit, Withdrawn Fenoldopam Fenoldopam may increase the hypotensive activities of Metyrosine. Approved Fentanyl Fentanyl may increase the sedative activities of Metyrosine. Approved, Illicit, Investigational, Vet Approved Ferulic acid Ferulic acid may increase the hypotensive activities of Metyrosine. Experimental Fexofenadine Fexofenadine may increase the sedative activities of Metyrosine. Approved, Investigational Flibanserin Flibanserin may increase the sedative activities of Metyrosine. Approved, Investigational Fluanisone Fluanisone may increase the sedative activities of Metyrosine. Experimental Fludiazepam Fludiazepam may increase the sedative activities of Metyrosine. Approved, Illicit Flunarizine Flunarizine may increase the sedative activities of Metyrosine. Approved Flunitrazepam Flunitrazepam may increase the sedative activities of Metyrosine. Approved, Illicit Fluoxetine The risk or severity of adverse effects can be increased when Metyrosine is combined with Fluoxetine. Approved, Vet Approved Flupentixol Flupentixol may increase the sedative activities of Metyrosine. Approved, Investigational, Withdrawn Fluphenazine Fluphenazine may increase the sedative activities of Metyrosine. Approved Flurazepam Flurazepam may increase the sedative activities of Metyrosine. Approved, Illicit, Investigational Fluspirilene Fluspirilene may increase the sedative activities of Metyrosine. Approved, Investigational Fluticasone propionate Fluticasone propionate may increase the sedative activities of Metyrosine. Approved Fluvoxamine Fluvoxamine may increase the sedative activities of Metyrosine. Approved, Investigational Fosinopril Fosinopril may increase the hypotensive activities of Metyrosine. Approved Fosphenytoin Fosphenytoin may increase the sedative activities of Metyrosine. Approved, Investigational Fospropofol Fospropofol may increase the sedative activities of Metyrosine. Approved, Illicit, Investigational Furazolidone Furazolidone may increase the hypotensive activities of Metyrosine. Approved, Investigational, Vet Approved Gabapentin Gabapentin may increase the sedative activities of Metyrosine. Approved, Investigational Gabapentin Enacarbil Gabapentin Enacarbil may increase the sedative activities of Metyrosine. Approved, Investigational Gamma Hydroxybutyric Acid Gamma Hydroxybutyric Acid may increase the sedative activities of Metyrosine. Approved, Illicit, Investigational Gepirone Gepirone may increase the sedative activities of Metyrosine. Investigational Glutethimide Glutethimide may increase the sedative activities of Metyrosine. Approved, Illicit Guanabenz Guanabenz may increase the hypotensive activities of Metyrosine. Approved, Investigational Guanadrel Guanadrel may increase the hypotensive activities of Metyrosine. Approved Guanazodine Metyrosine may increase the hypotensive activities of Guanazodine. Experimental Guanethidine Guanethidine may increase the hypotensive activities of Metyrosine. Approved Guanfacine Guanfacine may increase the sedative activities of Metyrosine. Approved, Investigational Guanoclor Metyrosine may increase the hypotensive activities of Guanoclor. Experimental Guanoxabenz Metyrosine may increase the hypotensive activities of Guanoxabenz. Experimental Guanoxan Metyrosine may increase the hypotensive activities of Guanoxan. Experimental Halazepam Halazepam may increase the sedative activities of Metyrosine. Approved, Illicit, Withdrawn Haloperidol Haloperidol may increase the sedative activities of Metyrosine. Approved Halothane Halothane may increase the sedative activities of Metyrosine. Approved, Vet Approved Harmaline Harmaline may increase the hypotensive activities of Metyrosine. Experimental Heroin Heroin may increase the sedative activities of Metyrosine. Approved, Illicit, Investigational Hexamethonium Hexamethonium may increase the hypotensive activities of Metyrosine. Experimental Hexobarbital Hexobarbital may increase the sedative activities of Metyrosine. Approved Hydracarbazine Hydracarbazine may increase the hypotensive activities of Metyrosine. Experimental Hydralazine Hydralazine may increase the hypotensive activities of Metyrosine. Approved Hydrochlorothiazide Hydrochlorothiazide may increase the hypotensive activities of Metyrosine. Approved, Vet Approved Hydrocodone Hydrocodone may increase the sedative activities of Metyrosine. Approved, Illicit Hydroflumethiazide Hydroflumethiazide may increase the hypotensive activities of Metyrosine. Approved, Investigational Hydromorphone Hydromorphone may increase the sedative activities of Metyrosine. Approved, Illicit Hydroxyzine Hydroxyzine may increase the sedative activities of Metyrosine. Approved Iloperidone The risk or severity of adverse effects can be increased when Metyrosine is combined with Iloperidone. Approved Iloprost Iloprost may increase the hypotensive activities of Metyrosine. Approved, Investigational Imidapril Imidapril may increase the hypotensive activities of Metyrosine. Investigational Imipramine The risk or severity of adverse effects can be increased when Metyrosine is combined with Imipramine. Approved Indalpine The risk or severity of adverse effects can be increased when Metyrosine is combined with Indalpine. Investigational, Withdrawn Indapamide Indapamide may increase the hypotensive activities of Metyrosine. Approved Indenolol Indenolol may increase the hypotensive activities of Metyrosine. Withdrawn Indiplon Indiplon may increase the sedative activities of Metyrosine. Investigational Indoramin Indoramin may increase the hypotensive activities of Metyrosine. Withdrawn Iprindole The risk or severity of adverse effects can be increased when Metyrosine is combined with Iprindole. Experimental Iproclozide Iproclozide may increase the hypotensive activities of Metyrosine. Withdrawn Iproniazid Iproniazid may increase the hypotensive activities of Metyrosine. Withdrawn Irbesartan Irbesartan may increase the hypotensive activities of Metyrosine. Approved, Investigational Isocarboxazid Isocarboxazid may increase the hypotensive activities of Metyrosine. Approved Isoflurane Isoflurane may increase the sedative activities of Metyrosine. Approved, Vet Approved Isradipine Isradipine may increase the hypotensive activities of Metyrosine. Approved, Investigational Ketamine Ketamine may increase the sedative activities of Metyrosine. Approved, Vet Approved Ketanserin Ketanserin may increase the hypotensive activities of Metyrosine. Investigational Ketazolam Ketazolam may increase the sedative activities of Metyrosine. Approved Ketobemidone Ketobemidone may increase the sedative activities of Metyrosine. Approved, Investigational Labetalol Labetalol may increase the hypotensive activities of Metyrosine. Approved Lacidipine Lacidipine may increase the hypotensive activities of Metyrosine. Approved, Investigational Lamotrigine Lamotrigine may increase the sedative activities of Metyrosine. Approved, Investigational Latanoprost Latanoprost may increase the hypotensive activities of Metyrosine. Approved, Investigational Lercanidipine Lercanidipine may increase the hypotensive activities of Metyrosine. Approved, Investigational Levetiracetam Levetiracetam may increase the sedative activities of Metyrosine. Approved, Investigational Levobupivacaine Levobupivacaine may increase the sedative activities of Metyrosine. Approved, Investigational Levocabastine Levocabastine may increase the sedative activities of Metyrosine. Approved, Investigational Levocetirizine Levocetirizine may increase the sedative activities of Metyrosine. Approved Levodopa Levodopa may increase the sedative activities of Metyrosine. Approved Levomethadyl Acetate Levomethadyl Acetate may increase the sedative activities of Metyrosine. Approved, Investigational Levomilnacipran The risk or severity of adverse effects can be increased when Metyrosine is combined with Levomilnacipran. Approved, Investigational Levorphanol Levorphanol may increase the sedative activities of Metyrosine. Approved Lidocaine Lidocaine may increase the sedative activities of Metyrosine. Approved, Vet Approved Linsidomine Linsidomine may increase the hypotensive activities of Metyrosine. Experimental Lisinopril Lisinopril may increase the hypotensive activities of Metyrosine. Approved, Investigational Lithium Lithium may increase the sedative activities of Metyrosine. Approved Lofentanil Lofentanil may increase the sedative activities of Metyrosine. Illicit Lofepramine The risk or severity of adverse effects can be increased when Metyrosine is combined with Lofepramine. Experimental Lofexidine Lofexidine may increase the hypotensive activities of Metyrosine. Approved, Investigational Loprazolam Loprazolam may increase the sedative activities of Metyrosine. Experimental Loratadine Loratadine may increase the sedative activities of Metyrosine. Approved, Investigational Lorazepam Lorazepam may increase the sedative activities of Metyrosine. Approved Lormetazepam Lormetazepam may increase the sedative activities of Metyrosine. Approved Losartan Losartan may increase the hypotensive activities of Metyrosine. Approved Loxapine Loxapine may increase the sedative activities of Metyrosine. Approved Lurasidone Lurasidone may increase the sedative activities of Metyrosine. Approved, Investigational Macitentan Metyrosine may increase the hypotensive activities of Macitentan. Approved Magnesium sulfate Magnesium sulfate may increase the sedative activities of Metyrosine. Approved, Investigational, Vet Approved Manidipine Manidipine may increase the hypotensive activities of Metyrosine. Approved, Investigational Maprotiline Maprotiline may increase the sedative activities of Metyrosine. Approved, Investigational Mebanazine Mebanazine may increase the hypotensive activities of Metyrosine. Withdrawn Mebicar Mebicar may increase the sedative activities of Metyrosine. Experimental Mecamylamine Mecamylamine may increase the hypotensive activities of Metyrosine. Approved, Investigational Meclizine Meclizine may increase the sedative activities of Metyrosine. Approved Medazepam Medazepam may increase the sedative activities of Metyrosine. Experimental Medetomidine Medetomidine may increase the sedative activities of Metyrosine. Vet Approved Melatonin Melatonin may increase the sedative activities of Metyrosine. Approved, Nutraceutical, Vet Approved Melperone Melperone may increase the sedative activities of Metyrosine. Approved, Investigational Mepivacaine Mepivacaine may increase the sedative activities of Metyrosine. Approved, Vet Approved Meprobamate Meprobamate may increase the sedative activities of Metyrosine. Approved, Illicit Meptazinol Meptazinol may increase the sedative activities of Metyrosine. Experimental Mesoridazine Mesoridazine may increase the sedative activities of Metyrosine. Approved, Investigational Metaxalone Metaxalone may increase the sedative activities of Metyrosine. Approved Methadone Methadone may increase the sedative activities of Metyrosine. Approved Methadyl Acetate Methadyl Acetate may increase the sedative activities of Metyrosine. Approved, Illicit Methapyrilene Methapyrilene may increase the sedative activities of Metyrosine. Withdrawn Methaqualone Methaqualone may increase the sedative activities of Metyrosine. Illicit, Withdrawn Methocarbamol Methocarbamol may increase the sedative activities of Metyrosine. Approved, Vet Approved Methohexital Methohexital may increase the sedative activities of Metyrosine. Approved Methoserpidine Metyrosine may increase the hypotensive activities of Methoserpidine. Experimental Methotrimeprazine Methotrimeprazine may increase the sedative activities of Metyrosine. Approved, Investigational Methoxyflurane Methoxyflurane may increase the sedative activities of Metyrosine. Approved, Investigational, Vet Approved Methsuximide Methsuximide may increase the sedative activities of Metyrosine. Approved Methyldopa Methyldopa may increase the hypotensive activities of Metyrosine. Approved Methylecgonine Methylecgonine may increase the sedative activities of Metyrosine. Experimental Methylene blue Methylene blue may increase the hypotensive activities of Metyrosine. Approved, Investigational Methylphenidate Methylphenidate may decrease the antihypertensive activities of Metyrosine. Approved, Investigational Methylphenobarbital Methylphenobarbital may increase the sedative activities of Metyrosine. Approved Metipranolol Metipranolol may increase the hypotensive activities of Metyrosine. Approved Metoclopramide The risk or severity of adverse effects can be increased when Metyrosine is combined with Metoclopramide. Approved, Investigational Metolazone Metolazone may increase the hypotensive activities of Metyrosine. Approved Metoprolol Metoprolol may increase the hypotensive activities of Metyrosine. Approved, Investigational Mibefradil Mibefradil may increase the hypotensive activities of Metyrosine. Investigational, Withdrawn Midazolam Midazolam may increase the sedative activities of Metyrosine. Approved, Illicit Milnacipran The risk or severity of adverse effects can be increased when Metyrosine is combined with Milnacipran. Approved, Investigational Minaprine Minaprine may increase the hypotensive activities of Metyrosine. Approved Minoxidil Minoxidil may increase the hypotensive activities of Metyrosine. Approved, Investigational Mirodenafil Mirodenafil may increase the antihypertensive activities of Metyrosine. Investigational Mirtazapine The risk or severity of adverse effects can be increased when Metyrosine is combined with Mirtazapine. Approved Moclobemide Moclobemide may increase the hypotensive activities of Metyrosine. Approved, Investigational Moexipril Moexipril may increase the hypotensive activities of Metyrosine. Approved Molindone Molindone may increase the sedative activities of Metyrosine. Approved Molsidomine Molsidomine may increase the hypotensive activities of Metyrosine. Approved, Investigational Moperone The risk or severity of adverse effects can be increased when Metyrosine is combined with Moperone. Experimental Morphine Morphine may increase the sedative activities of Metyrosine. Approved, Investigational Mosapramine The risk or severity of adverse effects can be increased when Metyrosine is combined with Mosapramine. Experimental Moxonidine Moxonidine may increase the hypotensive activities of Metyrosine. Approved, Investigational Muzolimine Muzolimine may increase the hypotensive activities of Metyrosine. Experimental Nabilone Nabilone may increase the sedative activities of Metyrosine. Approved, Investigational Nadolol Nadolol may increase the hypotensive activities of Metyrosine. Approved Naftopidil Naftopidil may increase the hypotensive activities of Metyrosine. Investigational Nalbuphine Nalbuphine may increase the sedative activities of Metyrosine. Approved Nebivolol Nebivolol may increase the hypotensive activities of Metyrosine. Approved, Investigational Nefazodone The risk or severity of adverse effects can be increased when Metyrosine is combined with Nefazodone. Approved, Withdrawn Nialamide Nialamide may increase the hypotensive activities of Metyrosine. Withdrawn Nicardipine Nicardipine may increase the hypotensive activities of Metyrosine. Approved, Investigational Nicorandil Nicorandil may increase the hypotensive activities of Metyrosine. Approved, Investigational Niguldipine Niguldipine may increase the hypotensive activities of Metyrosine. Experimental Nilvadipine Nilvadipine may increase the hypotensive activities of Metyrosine. Approved, Investigational Nimodipine Nimodipine may increase the hypotensive activities of Metyrosine. Approved, Investigational Nisoldipine Nisoldipine may increase the hypotensive activities of Metyrosine. Approved Nitrazepam Nitrazepam may increase the sedative activities of Metyrosine. Approved Nitrendipine Nitrendipine may increase the hypotensive activities of Metyrosine. Approved, Investigational Nitroprusside Nitroprusside may increase the hypotensive activities of Metyrosine. Approved, Investigational Nitrous oxide Nitrous oxide may increase the sedative activities of Metyrosine. Approved, Vet Approved Norflurane Norflurane may increase the sedative activities of Metyrosine. Approved, Investigational Normethadone Normethadone may increase the sedative activities of Metyrosine. Approved, Illicit Nortriptyline The risk or severity of adverse effects can be increased when Metyrosine is combined with Nortriptyline. Approved Obinutuzumab Metyrosine may increase the hypotensive activities of Obinutuzumab. Approved, Investigational Octamoxin Octamoxin may increase the hypotensive activities of Metyrosine. Withdrawn Olanzapine Olanzapine may increase the sedative activities of Metyrosine. Approved, Investigational Olmesartan Olmesartan may increase the hypotensive activities of Metyrosine. Approved, Investigational Olopatadine Olopatadine may increase the sedative activities of Metyrosine. Approved Omapatrilat Omapatrilat may increase the hypotensive activities of Metyrosine. Investigational Ondansetron Ondansetron may increase the sedative activities of Metyrosine. Approved Opipramol The risk or severity of adverse effects can be increased when Metyrosine is combined with Opipramol. Investigational Opium Opium may increase the sedative activities of Metyrosine. Approved, Illicit Orphenadrine Orphenadrine may increase the sedative activities of Metyrosine. Approved Osanetant Osanetant may increase the sedative activities of Metyrosine. Investigational Oxazepam Oxazepam may increase the sedative activities of Metyrosine. Approved Oxethazaine Oxethazaine may increase the sedative activities of Metyrosine. Approved, Investigational Oxprenolol Oxprenolol may increase the sedative activities of Metyrosine. Approved Oxybuprocaine Oxybuprocaine may increase the sedative activities of Metyrosine. Approved, Investigational Oxycodone Oxycodone may increase the sedative activities of Metyrosine. Approved, Illicit, Investigational Oxymorphone Oxymorphone may increase the sedative activities of Metyrosine. Approved, Investigational, Vet Approved Oxypertine The risk or severity of adverse effects can be increased when Metyrosine is combined with Oxypertine. Experimental Paliperidone Paliperidone may increase the sedative activities of Metyrosine. Approved Paraldehyde Paraldehyde may increase the sedative activities of Metyrosine. Approved, Investigational Pargyline Pargyline may increase the hypotensive activities of Metyrosine. Approved Paroxetine The risk or severity of adverse effects can be increased when Metyrosine is combined with Paroxetine. Approved, Investigational Penbutolol Penbutolol may increase the hypotensive activities of Metyrosine. Approved, Investigational Penfluridol Penfluridol may increase the sedative activities of Metyrosine. Experimental Pentazocine Pentazocine may increase the sedative activities of Metyrosine. Approved, Vet Approved Pentobarbital Pentobarbital may increase the sedative activities of Metyrosine. Approved, Investigational, Vet Approved Pentolinium Pentolinium may increase the hypotensive activities of Metyrosine. Approved Pentoxifylline Pentoxifylline may increase the hypotensive activities of Metyrosine. Approved, Investigational Perampanel Perampanel may increase the sedative activities of Metyrosine. Approved Perazine Perazine may increase the sedative activities of Metyrosine. Approved, Investigational Perindopril Perindopril may increase the hypotensive activities of Metyrosine. Approved Perospirone Perospirone may increase the sedative activities of Metyrosine. Approved Perphenazine Perphenazine may increase the sedative activities of Metyrosine. Approved Pethidine Pethidine may increase the sedative activities of Metyrosine. Approved Phenazocine Phenazocine may increase the sedative activities of Metyrosine. Experimental Phenelzine Phenelzine may increase the hypotensive activities of Metyrosine. Approved Phenibut Phenibut may increase the sedative activities of Metyrosine. Experimental Pheniprazine Pheniprazine may increase the hypotensive activities of Metyrosine. Withdrawn Phenobarbital Phenobarbital may increase the sedative activities of Metyrosine. Approved, Investigational Phenoperidine Phenoperidine may increase the sedative activities of Metyrosine. Experimental Phenoxybenzamine Phenoxybenzamine may increase the hypotensive activities of Metyrosine. Approved Phenoxyethanol Phenoxyethanol may increase the sedative activities of Metyrosine. Approved Phenoxypropazine Phenoxypropazine may increase the hypotensive activities of Metyrosine. Withdrawn Phentolamine Phentolamine may increase the hypotensive activities of Metyrosine. Approved Phenytoin Phenytoin may increase the sedative activities of Metyrosine. Approved, Vet Approved Pimozide Pimozide may increase the sedative activities of Metyrosine. Approved Pinacidil Pinacidil may increase the hypotensive activities of Metyrosine. Approved Pindolol Pindolol may increase the hypotensive activities of Metyrosine. Approved, Investigational Pipamperone Pipamperone may increase the sedative activities of Metyrosine. Approved, Investigational Pipotiazine The risk or severity of adverse effects can be increased when Metyrosine is combined with Pipotiazine. Approved, Investigational Piritramide Piritramide may increase the sedative activities of Metyrosine. Approved, Investigational Pirlindole Pirlindole may increase the hypotensive activities of Metyrosine. Approved Pivhydrazine Pivhydrazine may increase the hypotensive activities of Metyrosine. Withdrawn Pizotifen Pizotifen may increase the sedative activities of Metyrosine. Approved Platelet Activating Factor Platelet Activating Factor may increase the hypotensive activities of Metyrosine. Experimental Polythiazide Polythiazide may increase the hypotensive activities of Metyrosine. Approved Pomalidomide Pomalidomide may increase the sedative activities of Metyrosine. Approved Pramocaine Pramocaine may increase the sedative activities of Metyrosine. Approved Prazepam Prazepam may increase the sedative activities of Metyrosine. Approved, Illicit Prazosin Prazosin may increase the hypotensive activities of Metyrosine. Approved Pregabalin Pregabalin may increase the sedative activities of Metyrosine. Approved, Illicit, Investigational Prilocaine Prilocaine may increase the sedative activities of Metyrosine. Approved Primidone Primidone may increase the sedative activities of Metyrosine. Approved, Vet Approved Procaine Procaine may increase the sedative activities of Metyrosine. Approved, Investigational, Vet Approved Procarbazine Procarbazine may increase the hypotensive activities of Metyrosine. Approved, Investigational Prochlorperazine Prochlorperazine may increase the sedative activities of Metyrosine. Approved, Vet Approved Promazine Promazine may increase the sedative activities of Metyrosine. Approved, Vet Approved Promethazine The risk or severity of adverse effects can be increased when Metyrosine is combined with Promethazine. Approved, Investigational Propanidid Propanidid may increase the sedative activities of Metyrosine. Experimental Proparacaine Proparacaine may increase the sedative activities of Metyrosine. Approved, Vet Approved Propericiazine The risk or severity of adverse effects can be increased when Metyrosine is combined with Propericiazine. Approved, Investigational Propofol Propofol may increase the sedative activities of Metyrosine. Approved, Investigational, Vet Approved Propoxycaine Propoxycaine may increase the sedative activities of Metyrosine. Approved Propranolol Propranolol may increase the hypotensive activities of Metyrosine. Approved, Investigational Prothipendyl The risk or severity of adverse effects can be increased when Metyrosine is combined with Prothipendyl. Investigational Protriptyline The risk or severity of adverse effects can be increased when Metyrosine is combined with Protriptyline. Approved Proxibarbal Proxibarbal may increase the sedative activities of Metyrosine. Experimental PSD502 PSD502 may increase the sedative activities of Metyrosine. Investigational Quazepam Quazepam may increase the sedative activities of Metyrosine. Approved, Illicit Quetiapine Quetiapine may increase the sedative activities of Metyrosine. Approved Quinapril Quinapril may increase the hypotensive activities of Metyrosine. Approved, Investigational Quinine Quinine may increase the hypotensive activities of Metyrosine. Approved Quinisocaine Quinisocaine may increase the sedative activities of Metyrosine. Experimental Raclopride Raclopride may increase the sedative activities of Metyrosine. Investigational Ramelteon Ramelteon may increase the sedative activities of Metyrosine. Approved, Investigational Ramipril Ramipril may increase the hypotensive activities of Metyrosine. Approved Rasagiline Rasagiline may increase the hypotensive activities of Metyrosine. Approved Remifentanil Remifentanil may increase the sedative activities of Metyrosine. Approved Remikiren Remikiren may increase the hypotensive activities of Metyrosine. Approved Remoxipride Remoxipride may increase the sedative activities of Metyrosine. Approved, Withdrawn Rescinnamine Metyrosine may increase the hypotensive activities of Rescinnamine. Approved Reserpine Reserpine may increase the sedative activities of Metyrosine. Approved, Investigational Rilmenidine Rilmenidine may increase the hypotensive activities of Metyrosine. Approved, Investigational Riociguat Metyrosine may increase the hypotensive activities of Riociguat. Approved Risperidone Risperidone may increase the sedative activities of Metyrosine. Approved, Investigational Ritanserin Ritanserin may increase the sedative activities of Metyrosine. Investigational Rituximab Metyrosine may increase the hypotensive activities of Rituximab. Approved Romifidine Romifidine may increase the sedative activities of Metyrosine. Vet Approved Ropivacaine Ropivacaine may increase the sedative activities of Metyrosine. Approved Safrazine Safrazine may increase the hypotensive activities of Metyrosine. Withdrawn Saprisartan Saprisartan may increase the hypotensive activities of Metyrosine. Experimental Scopolamine Scopolamine may increase the sedative activities of Metyrosine. Approved, Investigational Secobarbital Secobarbital may increase the sedative activities of Metyrosine. Approved, Vet Approved Selegiline Selegiline may increase the hypotensive activities of Metyrosine. Approved, Investigational, Vet Approved Selexipag Selexipag may increase the hypotensive activities of Metyrosine. Approved Sepranolone Sepranolone may increase the sedative activities of Metyrosine. Investigational Sertindole Sertindole may increase the sedative activities of Metyrosine. Approved, Investigational, Withdrawn Sertraline The risk or severity of adverse effects can be increased when Metyrosine is combined with Sertraline. Approved Sevoflurane Sevoflurane may increase the sedative activities of Metyrosine. Approved, Vet Approved Sildenafil Sildenafil may increase the antihypertensive activities of Metyrosine. Approved, Investigational Sitaxentan Metyrosine may increase the hypotensive activities of Sitaxentan. Approved, Investigational, Withdrawn Sodium oxybate Sodium oxybate may increase the sedative activities of Metyrosine. Approved Spirapril Spirapril may increase the hypotensive activities of Metyrosine. Approved Stiripentol Stiripentol may increase the sedative activities of Metyrosine. Approved Sufentanil Sufentanil may increase the sedative activities of Metyrosine. Approved, Investigational Sulpiride Sulpiride may increase the sedative activities of Metyrosine. Approved, Investigational Sultopride Sultopride may increase the sedative activities of Metyrosine. Experimental Suvorexant Suvorexant may increase the sedative activities of Metyrosine. Approved, Investigational Tadalafil Tadalafil may increase the antihypertensive activities of Metyrosine. Approved, Investigational Talinolol Talinolol may increase the hypotensive activities of Metyrosine. Investigational Tandospirone Tandospirone may increase the sedative activities of Metyrosine. Investigational Tapentadol Tapentadol may increase the sedative activities of Metyrosine. Approved Tasimelteon Tasimelteon may increase the sedative activities of Metyrosine. Approved, Investigational Telmisartan Telmisartan may increase the hypotensive activities of Metyrosine. Approved, Investigational Temazepam Temazepam may increase the sedative activities of Metyrosine. Approved, Investigational Temocapril Temocapril may increase the hypotensive activities of Metyrosine. Experimental, Investigational Terlipressin Terlipressin may increase the hypotensive activities of Metyrosine. Approved, Investigational Tetrabenazine The risk or severity of adverse effects can be increased when Metyrosine is combined with Tetrabenazine. Approved, Investigational Tetracaine Tetracaine may increase the sedative activities of Metyrosine. Approved, Vet Approved Tetrahydropalmatine Tetrahydropalmatine may increase the sedative activities of Metyrosine. Investigational Tetrodotoxin Tetrodotoxin may increase the sedative activities of Metyrosine. Investigational Thalidomide Thalidomide may increase the sedative activities of Metyrosine. Approved, Investigational, Withdrawn Theodrenaline Theodrenaline may increase the hypotensive activities of Metyrosine. Investigational Thiamylal Thiamylal may increase the sedative activities of Metyrosine. Approved, Vet Approved Thiopental Thiopental may increase the sedative activities of Metyrosine. Approved, Vet Approved Thiopropazate The risk or severity of adverse effects can be increased when Metyrosine is combined with Thiopropazate. Experimental Thioproperazine The risk or severity of adverse effects can be increased when Metyrosine is combined with Thioproperazine. Approved Thioridazine Thioridazine may increase the sedative activities of Metyrosine. Approved, Withdrawn Thiothixene Thiothixene may increase the sedative activities of Metyrosine. Approved Tiagabine Tiagabine may increase the sedative activities of Metyrosine. Approved, Investigational Tianeptine The risk or severity of adverse effects can be increased when Metyrosine is combined with Tianeptine. Approved, Investigational Tiapride Tiapride may increase the sedative activities of Metyrosine. Approved, Investigational Tibolone Tibolone may increase the hypotensive activities of Metyrosine. Approved, Investigational Ticrynafen Ticrynafen may increase the hypotensive activities of Metyrosine. Withdrawn Tiletamine Tiletamine may increase the sedative activities of Metyrosine. Vet Approved Tilidine Tilidine may increase the sedative activities of Metyrosine. Experimental Timolol Timolol may increase the hypotensive activities of Metyrosine. Approved Tizanidine Tizanidine may increase the sedative activities of Metyrosine. Approved, Investigational Tolazoline Tolazoline may increase the hypotensive activities of Metyrosine. Approved, Vet Approved Tolcapone Tolcapone may increase the sedative activities of Metyrosine. Approved, Withdrawn Tolonidine Metyrosine may increase the hypotensive activities of Tolonidine. Experimental Toloxatone Toloxatone may increase the hypotensive activities of Metyrosine. Approved Topiramate Topiramate may increase the sedative activities of Metyrosine. Approved Torasemide Torasemide may increase the hypotensive activities of Metyrosine. Approved Tramadol Tramadol may increase the sedative activities of Metyrosine. Approved, Investigational Trandolapril Trandolapril may increase the hypotensive activities of Metyrosine. Approved Tranylcypromine Tranylcypromine may increase the sedative activities of Metyrosine. Approved, Investigational Travoprost Travoprost may increase the hypotensive activities of Metyrosine. Approved Trazodone Trazodone may increase the sedative activities of Metyrosine. Approved, Investigational Treprostinil Treprostinil may increase the hypotensive activities of Metyrosine. Approved, Investigational Triazolam Triazolam may increase the sedative activities of Metyrosine. Approved, Investigational Tricaine methanesulfonate Tricaine methanesulfonate may increase the sedative activities of Metyrosine. Vet Approved Trichlormethiazide Trichlormethiazide may increase the hypotensive activities of Metyrosine. Approved, Vet Approved Trichloroethylene Trichloroethylene may increase the sedative activities of Metyrosine. Approved Trifluoperazine Trifluoperazine may increase the sedative activities of Metyrosine. Approved, Investigational Trifluperidol Trifluperidol may increase the sedative activities of Metyrosine. Experimental Triflupromazine Triflupromazine may increase the sedative activities of Metyrosine. Approved, Vet Approved Trimazosin Trimazosin may increase the hypotensive activities of Metyrosine. Experimental Trimethaphan Trimethaphan may increase the hypotensive activities of Metyrosine. Approved, Investigational Trimipramine The risk or severity of adverse effects can be increased when Metyrosine is combined with Trimipramine. Approved Triprolidine Triprolidine may increase the sedative activities of Metyrosine. Approved Udenafil Udenafil may increase the antihypertensive activities of Metyrosine. Approved, Investigational Unoprostone Unoprostone may increase the hypotensive activities of Metyrosine. Approved, Investigational Urapidil Urapidil may increase the hypotensive activities of Metyrosine. Investigational Valproic Acid Valproic Acid may increase the sedative activities of Metyrosine. Approved, Investigational Valsartan Valsartan may increase the hypotensive activities of Metyrosine. Approved, Investigational Vardenafil Vardenafil may increase the antihypertensive activities of Metyrosine. Approved Venlafaxine The risk or severity of adverse effects can be increased when Metyrosine is combined with Venlafaxine. Approved Veralipride Veralipride may increase the sedative activities of Metyrosine. Experimental Vigabatrin Vigabatrin may increase the sedative activities of Metyrosine. Approved Vincamine Vincamine may increase the hypotensive activities of Metyrosine. Experimental Vinpocetine Vinpocetine may increase the hypotensive activities of Metyrosine. Investigational Vinyl ether Vinyl ether may increase the sedative activities of Metyrosine. Experimental Vortioxetine Vortioxetine may increase the sedative activities of Metyrosine. Approved, Investigational Xenon Xenon may increase the sedative activities of Metyrosine. Experimental Xipamide Xipamide may increase the hypotensive activities of Metyrosine. Experimental Xylazine Xylazine may increase the sedative activities of Metyrosine. Vet Approved Xylometazoline Xylometazoline may increase the hypotensive activities of Metyrosine. Approved, Investigational Yohimbine Yohimbine may decrease the antihypertensive activities of Metyrosine. Approved, Investigational, Vet Approved Zaleplon Zaleplon may increase the sedative activities of Metyrosine. Approved, Illicit, Investigational Ziconotide Ziconotide may increase the sedative activities of Metyrosine. Approved Zimelidine The risk or severity of adverse effects can be increased when Metyrosine is combined with Zimelidine. Withdrawn Ziprasidone Ziprasidone may increase the sedative activities of Metyrosine. Approved Zofenopril Zofenopril may increase the hypotensive activities of Metyrosine. Experimental Zolazepam Zolazepam may increase the sedative activities of Metyrosine. Vet Approved Zolpidem Zolpidem may increase the sedative activities of Metyrosine. Approved Zonisamide Zonisamide may increase the sedative activities of Metyrosine. Approved, Investigational Zopiclone Zopiclone may increase the sedative activities of Metyrosine. Approved Zotepine Zotepine may increase the sedative activities of Metyrosine. Approved, Investigational, Withdrawn Zuclopenthixol Zuclopenthixol may increase the sedative activities of Metyrosine. Approved, Investigational - Food Interactions
- Not Available
References
- Synthesis Reference
- US2868818
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0014903
- KEGG Drug
- D00762
- KEGG Compound
- C07921
- PubChem Compound
- 441350
- PubChem Substance
- 46506079
- ChemSpider
- 390103
- ChEBI
- 6912
- ChEMBL
- CHEMBL1200862
- Therapeutic Targets Database
- DAP000471
- PharmGKB
- PA450487
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Metyrosine
- ATC Codes
- C02KB01 — Metirosine
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Terminated Treatment Psychosis / Velo-Cardio-Facial Syndrome 1 3 Enrolling by Invitation Treatment Autonomic Nervous System Diseases / Dopamine Beta-Hydroxylase Deficiency / Idiopathic orthostatic hypotension / Orthostatic Intolerance 1 Not Available Suspended Diagnostic Bulimia Nervosa (BN) / Catechol-O-methyltransferase / Dopamine / Eating Disorders / Reward 1
Pharmacoeconomics
- Manufacturers
- Aton pharma inc
- Packagers
- Aton Pharma Inc.
- Draxis Specialty Pharmaceuticals Inc.
- Merck & Co.
- Dosage forms
Form Route Strength Capsule Oral 250 mg/1 - Prices
Unit description Cost Unit Demser 250 mg capsule 19.35USD capsule DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 312.5 °C PhysProp water solubility Very slightly soluble Not Available logP -1.7 Not Available - Predicted Properties
Property Value Source Water Solubility 2.48 mg/mL ALOGPS logP -1.9 ALOGPS logP -1.1 ChemAxon logS -1.9 ALOGPS pKa (Strongest Acidic) 2.06 ChemAxon pKa (Strongest Basic) 9.93 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 4 ChemAxon Hydrogen Donor Count 3 ChemAxon Polar Surface Area 83.55 Å2 ChemAxon Rotatable Bond Count 3 ChemAxon Refractivity 51.81 m3·mol-1 ChemAxon Polarizability 19.9 Å3 ChemAxon Number of Rings 1 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9918 Blood Brain Barrier - 0.8678 Caco-2 permeable - 0.7026 P-glycoprotein substrate Substrate 0.5286 P-glycoprotein inhibitor I Non-inhibitor 0.9891 P-glycoprotein inhibitor II Non-inhibitor 0.9926 Renal organic cation transporter Non-inhibitor 0.9278 CYP450 2C9 substrate Non-substrate 0.8025 CYP450 2D6 substrate Non-substrate 0.7432 CYP450 3A4 substrate Non-substrate 0.6887 CYP450 1A2 substrate Non-inhibitor 0.9459 CYP450 2C9 inhibitor Non-inhibitor 0.951 CYP450 2D6 inhibitor Non-inhibitor 0.9574 CYP450 2C19 inhibitor Non-inhibitor 0.9116 CYP450 3A4 inhibitor Non-inhibitor 0.892 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9735 Ames test Non AMES toxic 0.9695 Carcinogenicity Non-carcinogens 0.8681 Biodegradation Not ready biodegradable 0.7891 Rat acute toxicity 2.1516 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9852 hERG inhibition (predictor II) Non-inhibitor 0.9728
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as phenylpropanoic acids. These are compounds with a structure containing a benzene ring conjugated to a propanoic acid.
- Kingdom
- Organic compounds
- Super Class
- Phenylpropanoids and polyketides
- Class
- Phenylpropanoic acids
- Sub Class
- Not Available
- Direct Parent
- Phenylpropanoic acids
- Alternative Parents
- D-alpha-amino acids / Amphetamines and derivatives / Phenylpropanes / Aralkylamines / 1-hydroxy-2-unsubstituted benzenoids / Amino acids / Monocarboxylic acids and derivatives / Carboxylic acids / Organopnictogen compounds / Organic oxides show 3 more
- Substituents
- 3-phenylpropanoic-acid / Alpha-amino acid / Alpha-amino acid or derivatives / Amphetamine or derivatives / D-alpha-amino acid / Phenylpropane / 1-hydroxy-2-unsubstituted benzenoid / Aralkylamine / Phenol / Monocyclic benzene moiety show 18 more
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- non-proteinogenic L-alpha-amino acid, L-tyrosine derivative (CHEBI:6912)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Binder
- General Function
- Tyrosine 3-monooxygenase activity
- Specific Function
- Plays an important role in the physiology of adrenergic neurons.
- Gene Name
- TH
- Uniprot ID
- P07101
- Uniprot Name
- Tyrosine 3-monooxygenase
- Molecular Weight
- 58599.545 Da
References
- Nasrallah HA, Donnelly EF, Bigelow LB, Rivera-Calimlim L, Rogol A, Potkin S, Rauscher FP, Wyatt RJ: Inhibition of dopamine synthesis in chronic schizophrenia. Clinical ineffectiveness of metyrosine. Arch Gen Psychiatry. 1977 Jun;34(6):649-55. [PubMed:17374]
- Yoshimoto Y, Nakaso K, Nakashima K: L-dopa and dopamine enhance the formation of aggregates under proteasome inhibition in PC12 cells. FEBS Lett. 2005 Feb 14;579(5):1197-202. Epub 2005 Jan 21. [PubMed:15710413]
- Shore PA, Dorris RL: On a prime role for newly synthesized dopamine in striatal function. Eur J Pharmacol. 1975 Feb;30(2):315-8. [PubMed:1168577]
- Moore KE, Demarest KT, Johnston CA: Influence of prolactin on dopaminergic neuronal systems in the hypothalamus. Fed Proc. 1980 Sep;39(11):2912-6. [PubMed:7409209]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Drug created on June 13, 2005 07:24 / Updated on May 01, 2018 22:15